Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection

References

• Gallo R, Montagnier L. The discovery of HIV as the cause of AIDS. NEngl JMed. 2003;349:2283–2285.
   PubMed Web of Science ®Google Scholar
• Broder S, Gallo R. A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med. 1984;311:1292–1297.
   PubMed Web of Science ®Google Scholar
• Tenofovir. Summary of product characteristics. Foster City, CA: Gilead Sciences; 2010.
   Google Scholar
• Fung HB, Stone EA, Piacenti FJ. Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Clin Ther. 2002;24:34–45.
   Web of Science ®Google Scholar
• Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641–648.
   PubMed Web of Science ®Google Scholar
• Ray A, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297–3304.
   PubMed Web of Science ®Google Scholar
• Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71:619–627.
   PubMed Web of Science ®Google Scholar
• Mallants R, Van Oosterwyck K, Van Vaeck L, Mols R, De Clercq E, Augustijns P. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of teno- fovir disoproxil fumarate and its metabolites. Xenobiotica. 2005;35:1055–1066.
   PubMed Web of Science ®Google Scholar
• Miller DS. Nucleoside phosphonate interactions with multiple organic anion transporters in renal proximal tubule. J Pharmacol Exp Ther. 2001;299:567–574.
   PubMed Web of Science ®Google Scholar
• van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: Putative efflux pump for urinary cAMP and cGMP J Am SocNephrol. 2002;13:595–603.
   Web of Science ®Google Scholar
• Van Aubel R, Smeets PH, van den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol. 2005;288:F327-F333.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Liptrott N, Rodriguez-Novoa S. Genetic variants of ABCC10 are associated with kidney tubular dysfunction in patients treated with tenofovir-containing regimens. Abstr 742. Proceedings of the 17th Conference on Retroviruses and Opportunistic Infections, February 16–19, 2010, San Francisco, CA.
   Google Scholar
• Ray AS, Olson L, Fridland A. Role of purine nucleoside phosphorylase in interactions between 2″3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother. 2004;48:1089–1095.
   PubMed Web of Science ®Google Scholar
• Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278–283.
   PubMed Web of Science ®Google Scholar
• Malan N, Su J, Mancini M, et al. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: Data from the CASTLE study. AIDS Care. 2010;22:677–686.
   PubMed Web of Science ®Google Scholar
• Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated HIV-infected patients. Antimicrob Agents Chemother. 2004;48:2091–2096.
   PubMed Web of Science ®Google Scholar
• Tong L, Phan TK, Robinson KL, et al. Effects of HIV protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007;51:3498–3504.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Carten ML, Aquilante CL, et al. The effect of lopinavir/ ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008;83:265–272.
   PubMed Web of Science ®Google Scholar
• Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007;12:267–272.
   PubMed Web of Science ®Google Scholar
• Barrios A, Rendon A, Negredo E, et al. Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS. 2005;19:569–575.
   PubMed Web of Science ®Google Scholar
• Garcia-Benayas T, Rendon AL, Rodriguez-Novoa S, et al. Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. AIDS Res Hum Retroviruses. 2006;22:333–337.
   PubMed Web of Science ®Google Scholar
• Martinez E, Milinkovic A, de Lazzari E, et al. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV- infected adults. Lancet. 2004;364:65–67.
   PubMed Web of Science ®Google Scholar
• Lopez S, Negredo E, Garrabou G, et al. Longitudinal study on mitochondrial effects of didanosine-tenofovir combination. AIDS Res Hum Retroviruses. 2006;22:33–39.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Pozniak AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/ lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr. 2008;47:74–78.
   PubMed Web of Science ®Google Scholar
• Cassetti I, Madruga JV Suleiman JM, et al; Study 903E Team. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV- 1-infected patients. HIV Clin Trials. 2007;8:164–172.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292:191–201.
   PubMed Web of Science ®Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/ lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes: A 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535–540.
   PubMed Web of Science ®Google Scholar
• Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral- experienced patients: Results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257–1263.
   PubMed Web of Science ®Google Scholar
• Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med. 2003;139:313–320.
   PubMed Web of Science ®Google Scholar
• Martinez E, Arranz JA, Podzamczer D, et al; BICOMBO Study Team. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/ emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr. 2009;51:290–297.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49–57.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy, N Engl J Med. 2009;361:2230–2240.
   PubMed Web of Science ®Google Scholar
• Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: A randomized, 96-week trial. Clin InfectDis. 2009;49:1591–1601.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Sabin CA, Cartledge J, et al; RAVE (Randomized Abacavir versus Viread Evaluation) Group UK. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006;20:2043–2050.
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, et al; HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/ lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS. 2009;23:1547–1556.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999;4:87–94.
   PubMed Web of Science ®Google Scholar
• McColl DJ, Margot NA, Wulfsohn M, Coakley D, Cheng A, Miller M. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. J Acquir Immune Defic Syndr. 2004;37:1340–1350.
   PubMed Web of Science ®Google Scholar
• Von WV, Yerly S, Boni J, et al. Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis. 2008;46:1299–1309.
   Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al; 934 Study Group. Tenofovir DF, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV N Engl J Med. 2006;354:251–260.
   PubMed Web of Science ®Google Scholar
• Stellbrink HJ, Orkin C, Arribas JR. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir- emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963–972.
   PubMed Web of Science ®Google Scholar
• Estrada V, Fuster M. Darunavir in treatment-naive patients. The ARTEMIS study. Enferm Infecc Microbiol Clin. 2008;26 Suppl 10: S10-S13. Spanish.
   Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20:711–718.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al; CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricit- abine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. 2010;53:323–332.
   PubMed Web of Science ®Google Scholar
• Smith K, Weinberg W, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;28:5.
   Google Scholar
• Walmsley S, Avihingsanon A, Slim J, et al. Gemini: A non-inferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50:367–374.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant. 2005;20:743–746.
   PubMed Web of Science ®Google Scholar
• Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS. 2007;21:1273–1281.
   PubMed Web of Science ®Google Scholar
• Zimmermann AE, Pizzoferrato T, Bedford J, Morris A, Hoffman R, Braden G. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290.
   PubMed Web of Science ®Google Scholar
• Parsonage MJ, Wilkins EG, Snowden N, Issa BG, Savage MW. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. 2005;6:341–346.
   PubMed Web of Science ®Google Scholar
• Madeddu G, Bonfanti P, De Socio GV, et al. Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA project. Biomed Pharmacother. 2008;62:6–11.
   PubMed Web of Science ®Google Scholar
• Jones R, Stebbing J, Nelson M, et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J Acquir Immune Defic Syndr. 2004;37:1489–1495.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–1198.
   PubMed Web of Science ®Google Scholar
• Gerard L, Chazallon C, Taburet AM, Girard PM, Aboulker JC, Piketty C. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir. Antivir Ther. 2007;12:31–39.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis. 2008;197:102–108.
   PubMed Web of Science ®Google Scholar
• Mauss S, Berger F, Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS. 2005;19:93–95.
   PubMed Web of Science ®Google Scholar
• Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387–394.
   PubMed Web of Science ®Google Scholar
• Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are associated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7:105–111.
   PubMed Web of Science ®Google Scholar
• Fux CA, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study, Antivir Ther. 2007;12:1165–1173.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Kirk O, Gatell J, et al. Chronic renal failure among HIV- 1-infected patients. AIDS. 2007;21:1119–1127.
   PubMed Web of Science ®Google Scholar
• Bpharm S, Talbot A, Trottier B. Acute renal failure in four HIV-infected patients: Potential association with tenofovir and non-steroidal anti-inflammatory drugs. Can J Infect Dis Med Microbiol. 2008;19:75–76.
   PubMed Web of Science ®Google Scholar
• Coca S, Perazella M. Rapid communication: Acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci. 2002;324:342–344.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Baumelou A, Deray G. Acute renal failure in HIV patients. Nephrol Dial Transplant. 2007;22:2757–2762.
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Ansari N. Acute renal failure in an AIDS patient on tenofovir: A case report. J Med Case Reports. 2008;2:94.
   Google Scholar
• Vallecillo-Sanchez G, Guelar-Grimberg A, Gonzalez-Mena A, Knobel-Freud H. Acute renal failure associated with the use of teno- fovir combined with atazanavir in patients with HIV infection. Enferm Infecc Microbiol Clin. 2008;26:316–317. Spanish.
   PubMed Web of Science ®Google Scholar
• Malik A, Abraham P, Malik N. Acute renal failure and Fanconi syndrome in an AIDS patient on tenofovir treatment - case report and review of literature. J Infect. 2005;51:E61-E65.
   PubMedGoogle Scholar
• Dupont C, Meier F, Loupy A, Page B, Rouveix E. Acute renal failure and tenofovir: Two new cases. Antivir Ther. 2003;8(Suppl 1):76.
   Google Scholar
• Wood SM, Shah SS, Steenhoff AP, Meyers KE, Kaplan BS, Rutstein RM. Tenofovir-associated nephrotoxicity in two HIV-infected adolescent males. AIDS Patient Care STDS. 2009;23:14.
   Web of Science ®Google Scholar
• Callens S, De Roo A, Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J Infect. 2003;47:262–263.
   PubMed Web of Science ®Google Scholar
• Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am J Kidney Dis. 2002;40:1331–1333.
   PubMed Web of Science ®Google Scholar
• Creput C, Gonzalez-Canali G, Hill G, Piketty C, Kazatchkine M, Nochy D. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS. 2003;17:935–937.
   PubMed Web of Science ®Google Scholar
• Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC. Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: A report of 3 cases. AIDS Read. 2009;19:114–121.
   PubMed Web of Science ®Google Scholar
• Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–1073.
   PubMed Web of Science ®Google Scholar
• Mathew G, Knaus SJ. Acquired Fanconi’s syndrome associated with tenofovir therapy. J Gen Intern Med. 2006;21:C3-C5.
   PubMed Web of Science ®Google Scholar
• Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269–273.
   PubMed Web of Science ®Google Scholar
• Rifkin BS, Perazella MA. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–284.
   PubMed Web of Science ®Google Scholar
• Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir- related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: The role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174-e176.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696.
   PubMed Web of Science ®Google Scholar
• De la Prada FJ, Prados AM, Tugores A, Uriol M, Saus C, Morey A. Acute renal failure and proximal renal tubular dysfunction in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia. 2006;26:626–630. Spanish.
   PubMed Web of Science ®Google Scholar
• Di Biagio A, Rosso R, Monteforte P, Russo R, Rovetta G, Viscoli C. Whole body bone scintigraphy in tenofovir-related osteomalacia: A case report. J Med Case Reports. 2009;3:8136.
   Google Scholar
• Woodward CL, Hall AM, Williams IG, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482–487.
   PubMed Web of Science ®Google Scholar
• Childs KE, Fishman SL, Constable C, et al. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses. 2010;26:855–859.
   PubMed Web of Science ®Google Scholar
• Rosenvinge MM, Gedela K, Copas AJ, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54:496–499.
   PubMed Web of Science ®Google Scholar
• Schaaf B, Aries SP, Kramme E, Steinhoff J, Dalhoff K. Acute renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2003;37:e41-e43.
   PubMed Web of Science ®Google Scholar
• Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr. 2010;55:78–81.
   PubMed Web of Science ®Google Scholar
• Judd A, Boyd KL, Stohr W, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1 -infected children on antiretroviral therapy: A nested case-control study. AIDS. 2010;24:525–534.
   PubMed Web of Science ®Google Scholar
• Soler-Palacin P, Melendo S, Noguera-Julian A, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25:171–176.
   PubMed Web of Science ®Google Scholar
• Rosso R, Parodi A, Torrisi C, De Terlizzi F, Viscoli C, Vignolo M. A tailored dose of tenofovir could reduce its impact on bone mass in HIV Type 1-infected children and adolescents: A report from 5 years of clinical experience. AIDS Res Hum Retroviruses. 2010;26:1265–1266.
   Web of Science ®Google Scholar
• Riordan A, Judd A, Boyd K, Cliff D, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J. 2009;28:204–209.
   PubMed Web of Science ®Google Scholar
• Purdy JB, Gafni RI, Reynolds JC, Zeicher S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008;152:582–584.
   PubMed Web of Science ®Google Scholar
• Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711-e718.
   PubMed Web of Science ®Google Scholar
• Barrios A, Garcia-Benayas T, Gonzalez-Lahoz J, Soriano V Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004;18:960–963.
   PubMed Web of Science ®Google Scholar
• Gupta SK. Tenofovir-associated Fanconi syndrome: Review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99–103.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009;10:1675–1685.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481–1491.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, Soriano V et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study. Clin Infect Dis. 2009;48:e108-e116.
   PubMed Web of Science ®Google Scholar
• Ter Heine R, Huitema AD, Jansen RS, et al. Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure. Antivir Ther. 2009;14:299–301.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Labarga P, D’avolio A, et al. Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. AIDS. 2010;24:1064–1066.
   PubMed Web of Science ®Google Scholar
• Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52:1061–1068.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: A meta-analytic review. AIDS. 2006;20:2165–2174.
   PubMed Web of Science ®Google Scholar
• Grund B, Peng G, Gibert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS. 2009;23:1519–1529.
   PubMed Web of Science ®Google Scholar
• Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
   PubMed Web of Science ®Google Scholar
• Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res. 2004;19:402–409.
   PubMed Web of Science ®Google Scholar
• Holick MF, Vitamin D deficiency. NEngl J Med. 2007;357:266–281.
   PubMed Web of Science ®Google Scholar
• Labarga P, Barreiro P, Martin-Carbonero L, et al. Prevalence and mechanisms of hyperparathyroidism in HIV+ patients treated with TDF Abstr 824. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
   Google Scholar
• Steingrimsdottir L, Gunnarsson O, Indridason OS, Franzson L, Sigurdsson G. Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake. JAMA. 2005;294:2336–2341.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Res Hum Retroviruses. 2009;25:9–14.
   PubMed Web of Science ®Google Scholar
• Pocaterra D, Carenzi L, Ricci E, et al. TDF therapy is independently associated to hyperparathyroidism in HIV-infected treated patients. Abstr 825. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
   Google Scholar
• Havens P, Hazra R, Stephensen C, et al. Vitamin D3 supplementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: A randomized, double-blind, placebo-controlled multicenter trial: Adolescent Trials Network Study 63. Abstr 80. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011.
   Google Scholar
• Abdool KQ, Abdool SS, Fröhlich JA, et al; CAPRISA004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–1174.
   PubMed Web of Science ®Google Scholar
• Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–2599.
   PubMed Web of Science ®Google Scholar
• Benhamou Y, Tubiana R, Thibault V Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med. 2003;348:177–178.
   PubMed Web of Science ®Google Scholar
• Soriano V Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS. 2008;22:1399–1410.
   PubMed Web of Science ®Google Scholar
• Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol. 2008;48:391–398.
   PubMed Web of Science ®Google Scholar
• Puoti M, Airoldi M, Bruno R, et al. Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. AIDS Rev. 2002;4:27–35.
   PubMedGoogle Scholar
• Panel of Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents; 1–166. Department of Health and Human Services. January 10, 2011. Available at: http://aidsinfo.nih.gov/guidelines. Accessed May 10, 2011.
   Google Scholar
• Gatanaga H, Yazaki H, Tanuma J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS. 2007;21:264–265.
   PubMed Web of Science ®Google Scholar
• Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS. 2006;20:1621–1626.
   PubMed Web of Science ®Google Scholar
• Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther. 2001;23:1603–1614.
   PubMed Web of Science ®Google Scholar
• Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121–1122.
   PubMed Web of Science ®Google Scholar
• Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727–732.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS. 2004;18:2391–2400.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Influence of 516G > T polymorphisms at the gene encoding the CYP450–2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis. 2005;40:1358–1361.
   PubMed Web of Science ®Google Scholar
• Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15:1–5.
   PubMedGoogle Scholar
• Rotger M, Tegude H, Colombo S, et al. Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther. 2007;81:W557-W566.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21:41–46.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C > T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42:291–295.
   PubMed Web of Science ®Google Scholar
• Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis. 2005;192:1381–1386.
   PubMed Web of Science ®Google Scholar
• Back DJ, Khoo SH, Gibbons SE, Barry MG, Merry C. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit. 2000;22:122–126.
   PubMed Web of Science ®Google Scholar
• Brown KC, Paul S, Kashuba AD. Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet. 2009;48:211–241.
   PubMed Web of Science ®Google Scholar
• Duong M, Golzi A, Peytavin G, et al. Usefulness of therapeutic drug monitoring of antiretrovirals in routine clinical practice. HIV Clin Trials. 2004;5:216–223.
   PubMed Web of Science ®Google Scholar